Tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine clinical trials
How each study uses tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- MenACWY-TT
- 3
Studies by the year they started
3 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Canadian Immunization Research Network (1) · Pfizer (1) · Public Health England (1)
Often tested with
Tested in the same studies.
Meningococcal Vaccines (2)
Studies
Open first, then newest update. How each study uses tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Adolescent MenACWY Booster StudyCompletedPhase 4Canadian Immunization Research NetworkNCT03694405Written as MenACWY-TT
- A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).CompletedPhase 3PfizerNCT03189745Written as MenACWY-TT
- Comparison of Two Meningococcal ACWY Conjugate VaccinesCompletedPhase 2/3Public Health EnglandNCT01192997Written as MenACWY-TT
As the comparator · 2 — what is tested is compared with tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine
- Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate VaccineCompletedPhase 3Emory UniversityNCT05093829Written as MenACWY-TT
- Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy ToddlersCompletedPhase 2Novartis VaccinesNCT01994629Written as MenACWY-TT